found that plaque histopathology was reversed in the majority of patients with psoriasis after 12 weeks of treatment with sukinumab, suggesting that the activation of autophagy through inhibition of IL-17A facilitates plaque regression in patients (91). Here, IL17A is linked to psoriasis.